Postgenomics: Proteomics and Bioinformatics in Cancer Research

Halima Bensmail, Abdelali Haoudi

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Now that the human genome is completed, the characterization of the proteins encoded by the sequence remains a challenging task. The study of the complete protein complement of the genome, the "proteome" referred to as proteomics, will be essential if new therapeutic drugs and new disease biomarkers for early diagnosis are to be developed. Research efforts are already underway to develop the technology necessary to compare the specific protein profiles of diseased versus nondiseased states. These technologies provide a wealth of information and rapidly generate large quantities of data. Processing the large amounts of data will lead to useful predictive mathematical descriptions of biological systems which will permit rapid identification of novel therapeutic targets and identification of metabolic disorders. Here, we present an overview of the current status and future research approaches in defining the cancer cell's proteome in combination with different bioinformatics and computational biology tools toward a better understanding of health and disease.

Original languageEnglish
Pages (from-to)217-230
Number of pages14
JournalJournal of Biomedicine and Biotechnology
Volume2003
Issue number4
DOIs
Publication statusPublished - 29 Oct 2003
Externally publishedYes

Fingerprint

Proteome
Bioinformatics
Computational Biology
Proteomics
Genes
Biomarkers
Biological systems
Research
Technology
Neoplasms
Complement System Proteins
Proteins
Cells
Health
Human Genome
Early Diagnosis
Processing
Pharmaceutical Preparations
Genome
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Applied Microbiology and Biotechnology

Cite this

Postgenomics : Proteomics and Bioinformatics in Cancer Research. / Bensmail, Halima; Haoudi, Abdelali.

In: Journal of Biomedicine and Biotechnology, Vol. 2003, No. 4, 29.10.2003, p. 217-230.

Research output: Contribution to journalArticle

@article{b44ba915bae84c8ea1a34b68e736e0db,
title = "Postgenomics: Proteomics and Bioinformatics in Cancer Research",
abstract = "Now that the human genome is completed, the characterization of the proteins encoded by the sequence remains a challenging task. The study of the complete protein complement of the genome, the {"}proteome{"} referred to as proteomics, will be essential if new therapeutic drugs and new disease biomarkers for early diagnosis are to be developed. Research efforts are already underway to develop the technology necessary to compare the specific protein profiles of diseased versus nondiseased states. These technologies provide a wealth of information and rapidly generate large quantities of data. Processing the large amounts of data will lead to useful predictive mathematical descriptions of biological systems which will permit rapid identification of novel therapeutic targets and identification of metabolic disorders. Here, we present an overview of the current status and future research approaches in defining the cancer cell's proteome in combination with different bioinformatics and computational biology tools toward a better understanding of health and disease.",
author = "Halima Bensmail and Abdelali Haoudi",
year = "2003",
month = "10",
day = "29",
doi = "10.1155/S1110724303209207",
language = "English",
volume = "2003",
pages = "217--230",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",
number = "4",

}

TY - JOUR

T1 - Postgenomics

T2 - Proteomics and Bioinformatics in Cancer Research

AU - Bensmail, Halima

AU - Haoudi, Abdelali

PY - 2003/10/29

Y1 - 2003/10/29

N2 - Now that the human genome is completed, the characterization of the proteins encoded by the sequence remains a challenging task. The study of the complete protein complement of the genome, the "proteome" referred to as proteomics, will be essential if new therapeutic drugs and new disease biomarkers for early diagnosis are to be developed. Research efforts are already underway to develop the technology necessary to compare the specific protein profiles of diseased versus nondiseased states. These technologies provide a wealth of information and rapidly generate large quantities of data. Processing the large amounts of data will lead to useful predictive mathematical descriptions of biological systems which will permit rapid identification of novel therapeutic targets and identification of metabolic disorders. Here, we present an overview of the current status and future research approaches in defining the cancer cell's proteome in combination with different bioinformatics and computational biology tools toward a better understanding of health and disease.

AB - Now that the human genome is completed, the characterization of the proteins encoded by the sequence remains a challenging task. The study of the complete protein complement of the genome, the "proteome" referred to as proteomics, will be essential if new therapeutic drugs and new disease biomarkers for early diagnosis are to be developed. Research efforts are already underway to develop the technology necessary to compare the specific protein profiles of diseased versus nondiseased states. These technologies provide a wealth of information and rapidly generate large quantities of data. Processing the large amounts of data will lead to useful predictive mathematical descriptions of biological systems which will permit rapid identification of novel therapeutic targets and identification of metabolic disorders. Here, we present an overview of the current status and future research approaches in defining the cancer cell's proteome in combination with different bioinformatics and computational biology tools toward a better understanding of health and disease.

UR - http://www.scopus.com/inward/record.url?scp=0347362472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347362472&partnerID=8YFLogxK

U2 - 10.1155/S1110724303209207

DO - 10.1155/S1110724303209207

M3 - Article

AN - SCOPUS:0347362472

VL - 2003

SP - 217

EP - 230

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

IS - 4

ER -